Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $28.61 Analyst target: $41.50 Upside: 45.05%
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
See the full interactive analysis & chart →Informational only — not investment advice.